Introduction: Extravasations of chemotherapeutic drugs may lead to tissue necrosis and subsequent tissue defects, sometimes resulting in loss of function. In the absence of therapy, approximately one-third of vesicant extravasations will result in ulcerations, some of which necessitate plastic microsurgery to cover the soft tissue defects. The aim of this study was to describe the surgical technique itself and to present clinical results of the procedure in a clinical series of chemotherapeutic extravasation injuries that benefitted from a subcutaneous wash-out procedure (SWOP) by minimisation of serious complications.
Patients And Methods: Over a time period of 3 years, we treated 13 female patients following chemotherapeutic extravasation injury. Nine of the cases involved a high vesicant chemotherapy agent, and four patients involved chemotherapy with low vesicant potential. The therapeutic approach was performed using SWOP exclusively without the application of specific antidotes.
Results: The mean time interval between the extravasation injury and the SWOP was 345min (140-795min). In none of the cases was there a tissue breakdown, but there was a steady decrease in the inflammatory reaction of the cutaneous and subcutaneous soft tissues without additional complications over a 3-month follow-up period.
Conclusion: The results of the study suggest that SWOP is a minimally invasive, safe and effective emergency treatment for chemotherapeutic extravasation injury. Based on the absence of comparative studies with regard to the efficacy of conservative therapy, SWOP should be offered as a therapeutic option for chemotherapeutic extravasations, especially in cases of medical malpractice and also as a defence in case of a legal conflict.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.bjps.2010.04.040 | DOI Listing |
Comput Biol Med
December 2024
Grupo de Investigación e Innovación Ambiental (GIIAM), Institución Universitaria Pascual Bravo, Cl. 73 No 73A-226 (Bloque 8), Medellín, Colombia. Electronic address:
The systemic administration of chemotherapeutic drugs involves some reaction and transport mechanisms (RTMs), including perfusion along the blood vessels, extravasation, lymphatic drainage, interstitial and transmembrane transport, and protein association and dissociation, among others. When tissue is subjected to the controlled application of electric pulses (electroporation), the vessel wall and cell membrane are permeabilized, capillaries are vasoconstricted and tissue porosity is modified, affecting the RTMs during electro-chemotherapeutic treatments. This study is a theoretical investigation about the influence of the electric field magnitude (E), number of electroporation treatments (N) and duration of each electroporation protocol (T) on the presence, interaction and rates of the RTMs using in-house computational tools.
View Article and Find Full Text PDFFront Bioeng Biotechnol
October 2024
Biochemistry & Proteomics Laboratories, Department of Chemistry and Biochemistry, Clarkson University, Potsdam, NY, United States.
Our previous article entitled "Proteomics and its applications in breast cancer", proposed a Breast Cancer Continuum Concept (BCCC), including a Breast Cancer Cell Continuum Concept as well as a Breast Cancer Proteomic Continuum Concept. Breast cancer-on-chip (BCoC), breast cancer liquid biopsy-on-chip (BCLBoC), and breast cancer metastasis-on-chip (BCMoC) models successfully recapitulate and reproduce the principal mechanisms and events involved in BCCC. Thus, BCoC, BCLBoC, and BCMoC platforms allow for multiple cell lines co-cultivation to reproduce BC hallmark features, recapitulating cell proliferation, cell-to-cell communication, BC cell-stromal crosstalk and stromal activation, effects of local microenvironmental conditions on BC progression, invasion/epithelial-mesenchymal transition (EMT)/migration, intravasation, dissemination through blood and lymphatic circulation, extravasation, distant tissues colonization, and immune escape of cancer cells.
View Article and Find Full Text PDFJ Vasc Access
May 2024
Department of Nursing, People's Hospital of Deyang City, Deyang, Sichuan, China.
Wiley Interdiscip Rev Nanomed Nanobiotechnol
April 2024
Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio, USA.
Nanomedicine in oncology has not had the success in clinical impact that was anticipated in the early stages of the field's development. Ideally, nanomedicines selectively accumulate in tumor tissue and reduce systemic side effects compared to traditional chemotherapeutics. However, this has been more successful in preclinical animal models than in humans.
View Article and Find Full Text PDFEur J Hosp Pharm
December 2024
Dipartimento Farmaceutico Interaziendale, Azienda Unità Sanitaria Locale di Modena, Modena, Emilia-Romagna, Italy.
Brentuximab vedotin (BV) is an antibody-drug conjugate, consisting of a CD30-directed antibody, conjugated by a protease-cleavable linker to a microtubule disrupting agent auristatin E (MMAE). Although the safety datasheet of BV does not warn of severe toxic effects of extravasation, we report a third case of a patient with anaplastic large cell lymphoma who developed severe epidermal necrosis after extravasation. The reason for what happened could be attributed to the fact that MMAE belongs to the group of vinca alkaloids so it should be handled like other tissue-necrotising chemotherapeutics.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!